BMY.US Weekly Report · 2026-W43
BMY advanced 2.9% this week, but the headline gain masks sharp intra-week volatility. Early-week weakness persisted, then Phase 3 data wins on Wednesday–Thursday drove a rebound to 63.59, but Friday’s disclosure of a patient death in an autoimmune trial triggered a pullback to 61.48 in reduced volume. Valuations sit at historically extreme lows with earnings improving, yet mounting safety concerns and outflows suggest a temporary reprieve before the market reassesses risk.
Price Action
Closing price of 61.48, up 2.9% from last Friday’s close (59.75 on 10-16). The week displayed pronounced swings: high of 63.59 (10-22), low of 58.44 (10-19), for an intra-week range of 8.8%.
Three-stage progression: Monday gap-down (-1.4%) extended the prior decline; Tuesday–Wednesday recovery followed by Thursday’s surge to 63.00 (+3.1%) lifted the week’s peak; Friday pullback to 61.48 (-2.4%) in moderate volume of 9.76M shares.
Average weekly turnover of 9.64M shares with Friday’s 9.76M at mid-range levels—no extreme surge or collapse in activity. Turnover rate of 0.48% signals steady but not fervid participation.
Valuation and Earnings
Forward P/E stands at 13.53x, an exceptionally low level. Per valuation snapshot (10-22), P/E of 13.86x ranks at only the 4.54th percentile over the past three years—meaning the current price is cheaper than 95% of the past three years’ trading days, at an absolute floor.
Latest quarter (Q2 2026): EPS of 1.62 up 153% year-over-year; revenue of 12.97B up 5.7%; net profit up 153%. Profitability surging while revenue growth remains moderate.
Consensus forecast (10-23) pegs full-year EPS at 6.10 (median 5.99). Against TTM of 4.54, this implies material earnings acceleration in the remaining two quarters. The ultra-low valuation embeds significant upside potential, contingent on quarterly verification of sustained profit delivery.
Capital Flows
Mixed signals this week: large institutional buyers pulled 40.35M units net; mid-tier institutions withdrew 102.76M units net. Retail (small) orders added 86.25M units net. Net outflow of 56.87M units overall.
Capital exit timing aligns with Friday’s stock retreat, signaling rapid institutional de-risking in response to the patient death disclosure. Retail buying into the dip may reflect conviction in multi-year valuation support.
Institutional Perspective
Twenty-nine analysts: 6 Buy + 4 Strong Buy (10 bullish total), 17 Hold, 1 Sell. The rating composition leans constructive but remains dominated by Hold views.
Price targets range from 41.00 to 82.00, consensus at 65.42, implying 6.4% upside from Friday close. Most recent update on 10-23, post-negative news, creating potential information lag.
Weekly News Highlights
Clinical Progress vs. Safety Crisis framed this week’s narrative whiplash. Days 1–4 centered on positive data: RYZ101 (Rayzebio radiopharmaceutical) showed positive interim results in neuroendocrine tumor trials on 10-12; Izalontamab Brengitecan reduced progression/death risk by 59% in breast cancer. Both Phase 3 wins fueled Tuesday’s rebound. But Friday’s disclosure that a Breakfree-2 trial patient died of septic pneumonia in autoimmune disease suddenly inverted sentiment, prompting market reassessment of safety risk in the multiple sclerosis program and a direct Friday selloff.
R&D Partnerships underscore ongoing AI-driven innovation: Tempus AI expanded oncology data collaboration with BMY through 2031; Pathos AI formed drug-development partnership alongside Tempus, illustrating systematic investment in computational medicine.
Primary news items (ranked by materiality):
- Bristol-Myers Says After Breakfree-2 Study Data Cutoff, One haRMS Patient Experienced A Fatal Event Of Septic Pneumonia
- BUZZ-Bristol Myers discloses patient death in early-stage autoimmune disease trial; shares fall
- Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
- Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
- Bristol Myers Squibb Announces Positive Topline Results From The Interim Analysis Of Phase 3 ACTION-1 For RYZ101, Rayzebio’S Radiopharmaceutical Therapy, In Patients With GEP-NETS
- Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031
- Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development
- Erste Group Bank Has Positive Opinion of BMY FY2027 Earnings
- Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At Ms Toronto Occurred After Trial Pause
- Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On One
Takeaway
BMY exemplified this week the clash between fundamentals and event risk. Valuation sits at historic extremes (P/E in 4.54th percentile), clinical pipeline strengthening, and average price target 6.4% above current level. Yet the Friday Breakfree-2 patient death resurfaced safety concerns, upending the prior week’s bullish tilt and triggering systematic capital outflows.
Capital bifurcation—institutions fleeing, retail accumulating—signals unresolved market disagreement. Near-term price action will likely oscillate between “safety repricing” and “other programs’ momentum.” Recovery hinges on market digestion of the adverse event and Q3 results confirming underlying earnings power.